

Pharmaceuticals and Medical Devices Agency

This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Summary of investigation results Nivolumab (genetical recombination)

November 24, 2015

Non-proprietary name

Nivolumab (genetical recombination)

Brand name (Marketing authorization holder)

Opdivo Intravenous Infusions 20 mg, 100 mg (Ono Pharmaceutical Co., Ltd.)

Indications Radically unresectable malignant melanoma

Summary of revision

"Type 1 diabetes mellitus" should be newly added in the Clinically significant adverse reaction section.

Background of the revision and investigation results

Cases of type 1 diabetes mellitus including fulminant type 1 diabetes mellitus have been reported in patients treated with nivolumab in Japan. Following an investigation result based on the opinions of expert advisors and the available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary.

The number of reported adverse reactions and fatal cases in the last 3 fiscal years in Japan

A total of 5 cases associated with type 1 diabetes mellitus have been reported (including 4 cases for which a causal relationship to the product could not be ruled out). No fatality has been reported.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>